Encompass Health Corporation (EHC) Up 12.5% — Do I Chase the Rally?
Encompass Health Corporation (EHC) showed strong performance in the latest session, with the stock surging 12.48% to close at $111.99. Shares advanced sharply from the prior close of $99.56, gaining $12.43 in a single trading day and signaling robust bullish activity in the name. This decisive move pushes the stock meaningfully higher within its recent trading range on the NYSE and underscores solid upside momentum as investors bid the price higher.
Trading activity also gained ground, with volume coming in at 585,368 shares. While this was below the 90-day average of 968,425, the sizable price advance alongside steady turnover points to a constructive tone rather than a one-off spike. Even after the strong session, EHC remains below its 52-week high of $127.99 set on Oct. 24, 2025, leaving additional room before retesting that prior peak. From current levels, the stock would need to advance further to challenge that high, but the recent upswing marks a notable step in that direction.
Against major Health Care peers such as Medtronic (MDT), HCA Healthcare (HCA), and Cardinal Health (CAH), EHC’s latest percentage move stands out as particularly strong. While these names have seen their own periods of strength, the double-digit single-day gain for Encompass Health highlights a distinct burst of positive momentum. For now, price action clearly favors the bulls, with the stock advancing decisively and establishing a higher near-term reference point for traders and investors watching its trajectory.
Why Encompass Health Corporation Price is Moving Higher
Encompass Health Corporation’s latest leg higher is being driven primarily by a clean, broad-based earnings beat and confident forward guidance. The company’s Q4 2025 results, released on Feb. 5, showed adjusted EPS of $1.46, up from $1.17 a year earlier, with revenue climbing 9.9% year over year. Management highlighted 10.5% full-year revenue growth and the addition of 517 new beds, signaling that demand and capacity are expanding together. That combination of double-digit annual growth and visible investment in new facilities is reinforcing investor enthusiasm about the company’s ability to scale its inpatient rehabilitation footprint profitably.
The bullish sentiment intensified as Encompass Health paired its strong quarter with upbeat FY2026 guidance. The company is projecting EPS of $5.81–$6.10, with a midpoint that sits above consensus estimates, and revenue guidance of $6.37 billion–$6.47 billion. EBITDA guidance around $1.36 billion and an operating margin profile near 18.3% support the view that earnings growth is being driven by both volume and efficiency, not just top-line expansion. Same-store sales growth of 3.2% year over year further underscores healthy underlying demand. Positive analyst positioning adds an additional tailwind: a consensus “Buy” rating and average price targets in the $143–$150 range, with some firms reiterating “Overweight” views, validate the improving fundamental narrative. Together, these favorable developments are fueling the current upside momentum in Encompass Health shares.
What is the Encompass Health Corporation Rating - Should I Buy?
Weiss Ratings assigns EHC a B rating. Current recommendation is Buy. This places Encompass Health Corporation among the stronger names in the Health Care sector from a risk-adjusted perspective, signaling a favorable balance between potential return and downside risk for investors who can tolerate moderate volatility.
A key strength behind the B rating is the Excellent Growth Index, supported by revenue growth of 9.36% and a profit margin of 9.33%. The Good Efficiency Index, alongside a robust 24.41% return on equity, indicates that management is deploying capital effectively to generate shareholder value. Just as important, the Excellent Solvency Index points to a solid balance sheet, which can help the company navigate industry or economic stress while continuing to fund its growth strategy.
On the other hand, the Fair Total Return Index and Fair Volatility Index show that while performance has been competitive, it has not dramatically outpaced comparable stocks on a risk-adjusted basis. The Weak Dividend Index means income-oriented investors may find the stock less attractive purely as a yield play. However, these softer areas are not enough to offset the strength in growth, efficiency, and solvency that underpin the current Buy recommendation.
Within Health Care, Encompass Health sits with other quality peers such as Medtronic plc (MDT, B), HCA Healthcare, Inc. (HCA, B), and Cardinal Health, Inc. (CAH, B). For investors looking for exposure to the sector with an emphasis on operational strength and financial stability, EHC stands as a solid, growth-focused option.
About Encompass Health Corporation
Encompass Health Corporation (EHC) is a leading provider of post-acute health care services in the United States, with a primary focus on inpatient rehabilitation. The company operates one of the largest networks of inpatient rehabilitation hospitals, delivering intensive, physician-led care to patients recovering from conditions such as stroke, brain and spinal cord injuries, neurological disorders, complex orthopedic issues, and other serious illnesses. Its clinical model emphasizes interdisciplinary care teams, evidence-based treatment plans, and advanced rehabilitation technologies designed to help patients restore function, improve independence, and safely transition back to community settings.
The company’s health care delivery platform is built around specialized rehabilitation facilities that offer 24-hour nursing care, daily physician oversight, and highly coordinated therapy services. Encompass Health differentiates itself through scale, clinical specialization, and a deep focus on patient outcomes within the post-acute care continuum. Its hospitals work closely with acute-care hospitals, physicians, and payers to support appropriate care transitions and efficient resource use across the health care system. By maintaining a dedicated focus on inpatient rehabilitation and related health care services, Encompass Health has positioned itself as a key player in the health care equipment and services industry, serving a growing need for high-quality, cost-effective rehabilitative care in communities across the country.
Investor Outlook
With a B (Buy) Weiss Rating, Encompass Health Corporation (EHC) appears favorably positioned for investors seeking continued participation in the Health Care space. The focus now shifts to whether the stock can sustain recent momentum while maintaining the risk/reward balance implied by its current rating, especially as broader sector trends and company-specific execution unfold. See full rankings of all B-rated Health Care stocks inside the Weiss Stock Screener.
--